anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: Secondary hyperparathyroidism (SHPT) poses a common condition among patients with chronic kidney disease (CKD) due to the chronic stimulation of the parathyroid glands as a result of persistently low calcium levels. As a first option for medical treatment, vitamin D receptor analogs (VDRAs) and calcimimetic agents are generally used. Apart from cinacalcet, which is orally taken, in recent years, another calcimimetic agent, etelcalcetide, is being administered intravenously during dialysis. Materials and Methods: In a 5-year retrospective study between 2018 and 2023, 52 patients undergoing dialysis were studied. The aim of this study is to highlight the possible effects and/or benefits that intravenously administered calcimimetic agents have on CKD patients. A total of 34 patients (65.4%) received cinacalcet and etelcalcetide while parathormone (PTH) and calcium serum levels were monitored on a monthly basis. Results: A total of 29 out of 33 patients (87.9%) that received treatment with etelcalcetide showed a significant decrease in PTH levels, which rose up to 57% compared to the initial values. None of the included patients needed to undergo parathyroidectomy (PTx) due to either extremely high and persistent PTH levels or severe side effects of the medications. It is generally strongly advised that parathyroidectomies should be performed by an expert surgical team. In recent years, a significant decrease in parathyroidectomies has been recorded globally, a fact that is mainly linked to the constantly wider use of new calcimimetic agents. This decrease in parathyroidectomies has resulted in an important decrease in complications occurring in cervical surgeries (e.g., perioperative hemorrhage and nerve damage). Conslusions: Despite the fact that these surgical complications cannot be easily compared to the pharmaceutical side effects, the recorded decrease in parathyroidectomies is considered to be notable, especially in cases of relapse where a difficult reoperation would be considered based on previously published guidelines.
PROBLEM TO BE SOLVED: To establish an immunoassay system using an antibody inducted from amylin peptide by a constitution employing a technology for producing amyloid or rearranging DNA. SOLUTION: Amylin is produced in pancreas of a diabetic and precipitated as amyloid. Even a normal pancreas produces peptide having one or two different amylin and amino acid. Consequently, amylin and amylopeptide can be used as a stand and can be used as the probe of immunoassay when it is provided with a detectable label. An antibody is prepared for such antigen. the antibody is used as a specific probe for diabetic peptide (amylin) and also used in imminocytological chemistry and immunoassay. It is also used for diagnosis of a patient containing abnormal quantity of amylin in plasma. When the antibody is labeled, amylin existing in amyloid in the pancreas of a patient can be detected in vivo.
This is a single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. The primary objective of the study is to evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP. Men with Gleason score 7 (3+4) prostate cancer on one half of the prostate will receive TOOKAD® Soluble VTP under general anesthesia. Treatment will consist in hemiablation procedure designed to destroy the lobe of the prostate gland that contains the Gleason score 7 (3+4) cancer. Afterwards, patients will be followed for 5 years (60 months) with clinical evaluation, questionnaires on QOL, erectile and urinary functions, and PSA testing. In addition, treatment outcomes will be assessed based on prostate biopsy results at 3, 12, 24, 36, 48 and 60 months after the TOOKAD® Soluble treatment. All patients will undergo biopsy at 3 and 12 months. If the Month 3 biopsy is positive for any cancer, patients will be allowed a single re-treatment by TOOKAD® Soluble VTP to one or both lobes.
Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
This is a Phase 1 single-dose, randomized, 3-Period, crossover study conducted at a single center. A total of 30 healthy subjects, aged 18-45years, will be randomized to receive one of 3 treatment sequences. The duration of study will be approximately 18-26 days and subject participation will be the duration of study. Each treatment sequence will be enrolled in parallel and each subject will receive all 3 treatments in crossover fashion. Each subject will complete Screening, Baseline, and Treatment Phases. The Screening Phase will be conducted on an outpatient basis within 35 days of admission (Day -1 of Period 1). All subjects admitted to the study center the day before dosing in each treatment period (Day -1; check-in) for pre-dosing assessments and will remain in the study center through 48 hours post-dose for each Period. Final baseline qualification will only be evaluated prior to randomization for Treatment Period 1. Each one of the periods will be separated by a 3 (minimum) to 7 days (maximum) washout period. The Treatment Phase will be comprised of 3 crossover periods (duration Day-1 to 48 hours post dose). Each crossover period will include a single dose of study drug under fasting conditions followed by post-dose safety assessments and blood and urine collection for PK measures through 48 hours post-dose; each period will be separated by a 3 to 7 days washout. Subjects will remain in the study center for all 3- study treatment periods (Day -1 to 48 hours post dosing) and will be discharged after the 48-hour sampling timepoint (if safety parameters are acceptable to the Investigator on Day 3).
The following adverse events have been reported during post-approval use of Baclofen Injection. Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. 

Musculoskeletal: The onset of scoliosis or worsening of a pre-existing scoliosis has been reported. 

Urogenital: Sexual dysfunction in men and women, including decreased libido and orgasm dysfunction, have been reported. Erectile dysfunction in men has also been reported. Priapism has been reported following baclofen withdrawal. 

To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
1293563 Hydrolytic enzyme mixture ASTRA LAKEMEDEL AB 6 April 1970 [10 April 1969 25 Feb 1970] 18582/69 and 9179/70 Heading C3H A stable hydrolytic enzyme mixture which is a mixture of proteins is characterized in that it (a) has a U.V. spectrum characteristic of proteins containing aromatic amino acids, (b) is proteolytically active against casein, haemoglobin and gelatine, with a proteolytic optimum at pH 9-10 with casein, (c) hydrolyses N-α- tosyl-L-arginine ethyl ester, (d) contains proteolytic activity inducable by heating, (e) also contains esterases, lipases and amylases, (f) precipitates a heat stable enzyme with organic solvents (e.g. acetone) or ammonium sulphate, and (g) has stability and activity independent of Ca<SP>++</SP> ion concentration in solution. The mixture may be formed by fermenting Streptomyces globisporus variant NRRL 3762 under submerged aerobic conditions in a nutrient medium at, e.g. 26-30‹ C. and an initial pH of 6À0-7À5. A proteolytic enzyme fraction may be obtained from the enzyme mixture by subjecting it to gel filtration using a modified dextran having a fractionation range for peptides and globular proteins of molecular weight 1500-30,000 and eluting the dextran with water, or by contacting a solution of the enzymes with diethylaminoethyl cellulose and eluting the cellulose with ammonium acetate at pH 7À4, or by subjecting the enzyme mixture to isoelectric separation and recovering the fraction eluted at pH 4-6.
AIMS: Risk stratification of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS), diagnosed using breast biopsy, has great clinical significance. Clinical trials are currently exploring the possibility of active surveillance for low-risk lesions, whereas axillary lymph node staging may be considered during surgical planning for high-risk lesions. We aimed to develop a machine-learning algorithm based on whole-slide images of breast biopsy specimens and clinical information to predict the risk of upstaging to invasive breast cancer after wide excision.
METHODS AND RESULTS: Patients diagnosed with ADH/DCIS on breast biopsy were included in this study, comprising 592 (740 slides) and 141 (198 slides) patients in the development and independent testing cohorts, respectively. Histological grading of the lesions was independently evaluated by two pathologists. Clinical information, including biopsy method, lesion size, and Breast Imaging Reporting and Data System (BI-RADS) classification of ultrasound and mammograms, were collected. Deep DCIS consisted of three deep neural networks to evaluate nuclear grade, necrosis, and stromal reactivity. Deep DCIS output comprised five parameters: total patches, lesion extent, Deep Grade, Deep Necrosis, and Deep Stroma. Deep DCIS highly correlated with the pathologists' evaluations of both slide- and patient-level labels. All five parameters of Deep DCIS were significantly associated with upstaging to invasive carcinoma in subsequent wide excisional specimens. Using multivariate logistic regression, Deep DCIS predicted upstaging to invasive carcinoma with an area under the curve (AUC) of 0.81, outperforming pathologists' evaluation (AUC, 0.71 and 0.69). After including clinical and hormone receptor status information, performance further improved (AUC, 0.87). This combined model retained its predictive power in two subgroup analyses: the first subgroup included unequivocal DCIS (excluding cases of ADH and DCIS suspicious for microinvasion) (AUC, 0.83), while the second excluded cases of high-grade DCIS (AUC, 0.81). The model was validated in an independent testing cohort (AUC, 0.81).
CONCLUSION: This study demonstrated that deep-learning models can refine histological evaluation of ADH and DCIS on breast biopsies, which may help guide future treatment planning.
A computer-implemented system for a remote examination is disclosed. The computer-implemented system includes a treatment device, a master console, a user interface, and a control system. The treatment device comprises one or more slave sensors and a slave pressure system, the treatment device configured to be manipulated while a patient performs a treatment plan. The master console comprises a master device. The user interface comprises an output device configured to present telemedicine information associated with a telemedicine session. The control system comprises one or more processing devices operatively coupled to the master console and the treatment device. The one or more processing devices are configured to receive slave sensor data from the one or more slave sensors, use a manipulation of the master device to generate a manipulation instruction, transmit the manipulation instruction, and during the telemedicine session, use the manipulation instruction to cause the slave pressure system to activate.
Glucagon-like peptide 1 receptor (GLP-1R) agonist is an emerging anti-diabetic medication whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial. This study aimed to elucidate the roles of GLP-1R and its agonists on intrahepatic CCA (iCCA) progression. Expressions of GLP-1R in iCCA tissues investigated by immunohistochemistry showed that GLP-1R expressions were significantly associated with poor histological grading (P = 0.027). iCCA cell lines, KKU-055 and KKU-213A, were treated with exendin-4 and liraglutide, GLP-1R agonists, and their effects on proliferation and migration were assessed. Exendin-4 and liraglutide did not affect CCA cell proliferation in vitro, but liraglutide significantly suppressed the migration of CCA cells, partly by inhibiting epithelial-mesenchymal transition. In contrast, liraglutide significantly reduced CCA tumor volumes and weights in xenografted mice (P = 0.046). GLP-1R appeared downregulated when CCA cells were treated with liraglutide in vitro and in vivo. In addition, liraglutide treatment significantly suppressed Akt and STAT3 signaling in CCA cells, by reducing their phosphorylation levels. These results suggested that liraglutide potentially slows down CCA progression, and further clinical investigation would benefit the treatment of CCA with diabetes mellitus.
A composition for preventing and treating arthritis which contains Lonicera japonica THUNB and Anemarrhena asphodeloides BUNGE is provided to suppress inflammatory cytokine and mediator and reduce pain. A pharmaceutical composition for preventing and treating arthritis comprises a mixture crude extract of Lonicera japonica THUNB and Anemarrhena asphodeloides BUNGE as an active ingredient. The extract is crude extract or butanol soluble extract. The crude extract is obtained by using water, low alcohol of 1-4 carbon atoms, or their mixture solvent. The extract comprises 0.5-6(w/w%) of chlorogenic acid or 0.5-4(w/w%) of mangiferin. The arthritis is degenerative arthritis, rheumatoid arthritis, or lupus arthritis.
An adhesive compsn. for surfaces moistened with a liquid comprises hydroxypropyl-methylcellulose (HPMC) and at least one additional component which modifies swelling. Also claimed is a method for determining the adhesion time of adhesive compsns. for surfaces moistened with a liquid, comprising: a) applying the compsn. to a test surface in a device; b) introducing the device into a releasing apparatus contg. an appropriate acceptor medium; c) removing the compsn. from the test surface by applying hydrodynamic and/or kinematic forces; and d) registering this removal on a time basis. A device for determining the adhesion time of adhesive compsns. for surfaces moistened with a liquid is also claimed, and comprises: i) a housing (1); ii) a base-plate (2) inserted in the housing; and iii) an internal ring (3) which does not come up to the top of the housing.  Pref. the component which modifies swelling is conveniently a substance which is difficultly soluble at least in aq. media and which retards solvent uptake by HPMC, esp. crosslinked polyvinyl pyrrolidone, or TiO2, talc or SiO2.
Introduction: Hands are commonly affected in Systemic sclerosis (SS). Skin thickening, Raynaud phenomenon, digital ulcers and cutaneous calcinosis may result in pain, disability and claw deformity. Strategies to improve hand function are recommended since its diagnosis and throughout the treatment. Unfortunately hand care assistance is not often available. The objective of this study was to developed a brief guide about hand care and home-based exercises to be applied in our outpatient clinic.

Methods: A brief program , with instructions about the disease and home-based exercises will be applied in a group patients with Systemic Sclerosis (SS) during the period of 12 weeks. Hand function (Cochin Hand and Functional Scale), disability (HAQ-Scleroderma), quality of life (SF-36 hand pain (visual analogue scale), grip and pinch strength, hand mobility (delta finger) will be assessed in the first appointment and after twelve weeks.
All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
Patients receive azenosertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease.
PCT No. PCT/SU91/00168 Sec. 371 Date Dec. 22, 1992 Sec. 102(e) Date Dec. 22, 1992 PCT Filed Aug. 19, 1991 PCT Pub. No. WO93/04034 PCT Pub. Date Mar. 4, 1993.A novel crystalline modification of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride and a method for production of said compound residing in that a solution of 2-dimethylaminoethyl-n-butylaminobenzoate hydrochloride of polymorphic form in water or organic solvent, or in their mixture, is cooled by a cooling agent at a rate of no less than 8 DEG  C./min till complete crystallization of the solution with subsequent drying of obtained crystals. Compound of the invention has a local anaesthetic activity and is an active principle of a pharmaceutical preparation for anaesthesia of eyes (content of active principle is from 0.05 to 0.5% by mass).
Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Analgesia with ULTIVA in the immediate postoperative period (until approximately 30 minutes after extubation) was studied in 401 patients in four dose-finding studies and in 281 patients in two efficacy studies. In the dose-finding studies, the use of bolus doses of ULTIVA and incremental infusion rate increases ≥ 0.05 mcg/kg/min led to respiratory depression and muscle rigidity. 

In two efficacy studies, ULTIVA 0.1 mcg/kg/min was started immediately after discontinuing anesthesia. Incremental infusion rate increases of 0.025 mcg/kg/min every 5 minutes were given to treat moderate to severe postoperative pain. In Study 1, 50% decreases in infusion rate were made if respiratory rate decreased below 12 breaths/min and in Study 2, the same decreases were made if respiratory rate was below 8 breaths/min. With this difference in criteria for infusion rate decrease, the incidence of respiratory depression was lower in Study 1 (4%) than in Study 2 (12%). In both studies, ULTIVA provided effective analgesia (no or mild pain with respiratory rate ≥ 8 breaths/min) in approximately 60% of patients at mean final infusion rates of 0.1 to 0.125 mcg/kg/min.

Study 2 was a double-blind, randomized, controlled study in which patients received either morphine sulfate (0.15 mg/kg administered 20 minutes before the anticipated end of surgery plus 2 mg bolus doses for supplemental analgesia) or ULTIVA (as described above). Emergence from anesthesia was similar between groups; median time to extubation was 5 to 6 minutes for both. ULTIVA provided effective analgesia in 58% of patients compared to 33% of patients who received morphine. Respiratory depression occurred in 12% of patients receiving ULTIVA compared to 4% of morphine patients. For patients who received ULTIVA, morphine sulfate (0.15 mg/kg) was administered in divided doses 5 and 10 minutes before discontinuing ULTIVA. Within 30 minutes after discontinuation of ULTIVA, the percentage of patients with effective analgesia decreased to 34%.
Leber congenital amaurosis (LCA) and early-onset retinal degeneration (EORD) are inherited retinal diseases (IRD) characterized by early-onset vision impairment. Herein, we studied 15 Saudi families by whole exome sequencing (WES) and run-of-homozygosity (ROH) detection via AutoMap in 12/15 consanguineous families. This revealed (likely) pathogenic variants in 11/15 families (73%). A potential founder variant was found in RPGRIP1. Homozygous pathogenic variants were identified in known IRD genes (ATF6, CRB1, CABP4, RDH12, RIMS2, RPGRIP1, SPATA7). We established genotype-driven clinical reclassifications for ATF6, CABP4, and RIMS2. Specifically, we observed isolated IRD in the individual with the novel RIMS2 variant, and we found a retina-enriched RIMS2 isoform conserved but not annotated in mouse. The latter illustrates potential different phenotypic consequences of pathogenic variants depending on the particular tissue/cell-type specific isoforms they affect. Lastly, a compound heterozygous genotype in GUCY2D in one non-consanguineous family was demonstrated, and homozygous variants in novel candidate genes ATG2B and RUFY3 were found in the two remaining consanguineous families. Reporting these genes will allow to validate them in other IRD cohorts. Finally, the missing heritability of the two unsolved IRD cases may be attributed to variants in non-coding regions or structural variants that remained undetected, warranting future WGS studies.
14,15-Dihydro-20,21-dinor-14-eburnameninol (I) is used to prepare a pharmaceutical composition for treating or preventing major depression. 14,15-Dihydro-20,21-dinor-14-eburnameninol of formula (I), where the hydrogens at positions 3 and 16 are trans and the hydroxy group is in alpha or beta conformation, is used to prepare a pharmaceutical composition for treating or preventing major depression. An independent claim is also included for the use of (I) to prepare a pharmaceutical composition for treating patients with depression resistant to conventional antidepressants in order to make such patients sensitive to conventional antidepressant treatment. [Image] ACTIVITY : Antidepressant. No biological data given. MECHANISM OF ACTION : None given.
Subjects will receive a low-fat breakfast 30 minutes before AZD5055 film-coated tablet administered together with rabeprazole on Day 17. Rabeprazole will continue twice daily, the last dose is on the evening of Study Day 18 in Period 5.
Centers that are randomly assigned to the control group will continue with regularly schedule programing and activities. Families recruited from control centers will be allowed to take part in all the programs offered at the recreation centers, with exception to the AFL program since it will not be offered at those centers. Control group families will also receive publicly available information regarding the benefits of PA and strategies to become physically active (e.g., CDC PA guidelines websites \& handbook). 12-month sustainability phase will involve assessments at the organizational and individual levels. At the organizational level, we will examine the number of AFL sessions held at each recreation center and document the number of phone consultations, length of calls, and barriers addressed. At the individual level, we will examine the number of minutes of adult and child habitual PA.
This study was conducted on 40 male patients aged 20 to 40 suffering from LBP. Patients were included in the study if they had hyperkyphosis with an X-ray cobb's angle greater than 40 degrees. The visual analogue scale (VAS), the Oswestry disability questionnaire (ODI), and Cobb's angle were assessed for all patients before and one month post-intervention. Patients who met the inclusion criteria and agreed to participate in this study were randomly assigned to one of the two groups. Group 1 (the control group) received the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise. Group 2 (the study group) received the triple attack protocol which includes a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a \[14C\]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.